Funds › Lynx1 Capital Management LP
Lynx1 Capital Management LP
13F for Q2 2026, filed Aug 13, 2026. 27 positions worth $865.5M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Lynx1 Capital Management LP in the latest 13F quarter?
Using 13F.ai, how has Lynx1 Capital Management LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Lynx1 Capital Management LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | GHRS GH Research PLC | 13.26M | $356.5M | 41.2% | +23.2% | 13F ↗ |
| 2 | CGEM Cullinan Therapeutics, Inc. | 8.96M | $163.2M | 18.9% | Unchanged | 13F ↗ |
| 3 | STOK Stoke Therapeutics, Inc. | 4.04M | $132.1M | 15.3% | -15.2% | 13F ↗ |
| 4 | AGIO Agios Pharmaceuticals, Inc. | 3.41M | $126.5M | 14.6% | +30.5% | 13F ↗ |
| 5 | CCCC C4 Therapeutics, Inc. | 7.33M | $34.2M | 4.0% | +4.7% | 13F ↗ |
| 6 | KRRO Korro Bio, Inc. | 1.54M | $20.3M | 2.3% | Unchanged | 13F ↗ |
| 7 | TCRX TScan Therapeutics, Inc. | 8.02M | $7.9M | 0.9% | Unchanged | 13F ↗ |
| 8 | DTIL Precision BioSciences, Inc. | 950,466 | $7.5M | 0.9% | -3.5% | 13F ↗ |
| 9 | NEUP Neuphoria Therapeutics Inc. | 875,328 | $3.8M | 0.4% | Unchanged | 13F ↗ |
| 10 | PASG Passage Bio, Inc. | 673,759 | $3.3M | 0.4% | +8.0% | 13F ↗ |
| 11 | CGON CG Oncology, Inc. | 31,391 | $2.2M | 0.3% | -0.6% | 13F ↗ |
| 12 | PLRX Pliant Therapeutics, Inc. | 1.80M | $2.0M | 0.2% | New | 13F ↗ |
| 13 | TRDA Entrada Therapeutics, Inc. | 178,606 | $1.3M | 0.2% | -15.6% | 13F ↗ |
| 14 | Vyne Therapeutics Inc | 1.63M | $1.1M | 0.1% | Unchanged | 13F ↗ |
| 15 | PRQR ProQR Therapeutics N.V. · Shs Euro | 521,413 | $969.8K | 0.1% | +661% | 13F ↗ |
| 16 | TRAW Traws Pharma, Inc. | 559,470 | $471.8K | 0.1% | +3611% | 13F ↗ |
| 17 | FHTX Foghorn Therapeutics Inc. | 61,588 | $300.5K | <0.1% | New | 13F ↗ |
| 18 | DNLI Denali Therapeutics Inc. | 11,658 | $299.8K | <0.1% | -99.4% | 13F ↗ |
| 19 | XNCR Xencor, Inc. | 18,194 | $292.9K | <0.1% | -96.6% | 13F ↗ |
| 20 | ABSI Absci Corporation | 21,245 | $246.2K | <0.1% | Unchanged | 13F ↗ |
| 21 | HOWL Werewolf Therapeutics, Inc. | 657,786 | $236.7K | <0.1% | Unchanged | 13F ↗ |
| 22 | IMTX Immatics N.V. | 23,236 | $235.4K | <0.1% | -89.3% | 13F ↗ |
| 23 | AVTX Avalo Therapeutics, Inc. | 10,100 | $186.6K | <0.1% | New | 13F ↗ |
| 24 | BOLT Bolt Biotherapeutics, Inc. | 30,800 | $118.6K | <0.1% | Unchanged | 13F ↗ |
| 25 | NUVB Nuvation Bio Inc. | 16,029 | $91.0K | <0.1% | New | 13F ↗ |
| 26 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 10,000 | $66.1K | <0.1% | New | 13F ↗ |
| 27 | IKT Inhibikase Therapeutics, Inc. | 20,000 | $40.6K | <0.1% | New | 13F ↗ |
Changes since Q1 2026
6 new, 6 added to, 7 trimmed, 2 exited, 8 unchanged. By estimated dollars.
New positions (6)
| PLRX Pliant Therapeutics, Inc. | 1.80M | New | $2.0M |
| FHTX Foghorn Therapeutics Inc. | 61,588 | New | $300.5K |
| AVTX Avalo Therapeutics, Inc. | 10,100 | New | $186.6K |
| NUVB Nuvation Bio Inc. | 16,029 | New | $91.0K |
| EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 10,000 | New | $66.1K |
| IKT Inhibikase Therapeutics, Inc. | 20,000 | New | $40.6K |
Added to (6)
Trimmed (7)
| DNLI Denali Therapeutics Inc. | 11,658 | -99.4% | -$48.1M |
| STOK Stoke Therapeutics, Inc. | 4.04M | -15.2% | -$23.7M |
| XNCR Xencor, Inc. | 18,194 | -96.6% | -$8.3M |
| IMTX Immatics N.V. | 23,236 | -89.3% | -$2.0M |
| DTIL Precision BioSciences, Inc. | 950,466 | -3.5% | -$272.3K |
| TRDA Entrada Therapeutics, Inc. | 178,606 | -15.6% | -$243.5K |
| CGON CG Oncology, Inc. | 31,391 | -0.6% | -$14.2K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | 13F-HR/A (restatement) | 27 | $865.5M | Current | SEC ↗ |
| Q2 2026 | Aug 12, 2026 | 13F-HR | 23 | $507.6M | Replaced | SEC ↗ |
| Q1 2026 | May 4, 2026 | 13F-HR | 23 | $632.7M | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 22 | $494.0M | Current | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | 13F-HR | 14 | $491.3M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 15 | $346.2M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 14 | $279.2M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer